- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03002935
A Safety Study of Orally Administered BPM31510 in Healthy Subjects
A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM31510 in Healthy Subjects
Study Overview
Detailed Description
Study subjects will be admitted to the clinic on Day -1. All subjects will self-administer the Day 1 doses of study drug under supervision of the clinic staff. Doses of 3200 mg will be administered three times per day before meals.
Dosing will continue for an additional 14 days on an outpatient basis with Day 5 morning dose and the last study dose on Day 15 to be administered at the clinic (one morning dose, is given on Day 15).
On Days 1, 2, 5 and 15, pharmacokinetic (PK) and pharmacodynamics (PD) sampling will be performed 30 minutes prior to the first dose, and 0.5, 1, 2, and 4 hours after the first dose at all visits with an additional PK draw on Day 1 at 0.5, 1, 2, and 4 after the second dose. Urine for PK/PD will be collected pre-dose on Day 1, Day 2, Day 5 and Day 15. At all visits (on Days 1, 2, 5 and at the final dose on Day 15), samples will be collected for chemistry, Complete Blood Count (CBC), International normalized ratio (INR), prothrombin time (PT), partial thromboplastin time (PTT), cholesterol, low density lipoprotein (LDL), and high density lipoprotein (HDL), and vitamin K level. Blood samples for PK/PD will be collected 30 minutes prior to the morning dose on Day 5 and Day 15 and also at 0.5, 1, 2, and 4 hours after dosing. Lab samples (chemistry, etc.), will also be drawn at the time of the first PK/PD draw on Day 5 and Day 15.
A phone interview will be conducted no fewer than 25 days and no more than 35 days after the last dose on Day 15 to collect information on concomitant medications and adverse events Graded using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Eatontown, New Jersey, United States, 07724
- Clinilabs Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women, age >18 years
- Body mass index (BMI)≥19 and ≤30
- Good health conditions or without significant illness, by judgment of a legally qualified professional, according to the following evaluations: medical history, physical examination, vital signs, electrocardiogram (ECG), and screening or baseline hematology and clinical chemistry measures.
Subjects of child bearing potential must agree to use one of the accepted methods of contraception (listed below) during the trial (including the screening period prior to receiving trial medication), at least until return of menstruation after stopping the trial medication.
- condom (male or female) with spermicide
- diaphragm or cervical cap with spermicide
- Intrauterine device (IUD)
- hormonal contraception and condom (male or female)
- Female subjects must have a negative pregnancy test result at screening and Day-1
- PT/PTT/INR within normal limits
- Vitamin K levels within normal limits
- Capable of understanding and complying with the protocol and signing informed consent
Exclusion Criteria:
- Pregnant or lactating female subjects
- Known hypersensitivity to the study drug (Coenzyme Q10) or to compounds chemically related
- History or presence of hepatic or gastrointestinal illnesses, or other condition that interferes with the drug's absorption, distribution, excretion or metabolism
- History of hepatic, renal, pulmonary, gastrointestinal, epileptic, hematologic or psychiatric illness
- Hypotension or hypertension of any etiologic that needs pharmacologic treatment
- History of or existing coagulopathy
- History of myocardial infarction, angina, and/or heart insufficiency
- Non-recommended electrocardiographic findings, according to investigator criteria
- Results of the laboratory exams out of normal range unless that they are considered as clinically irrelevant by the investigator
- Subject is a smoker
- Subject ingests more than 5 cups of coffee or tea a day
- History of alcohol or drug abuse
- History of serious adverse reactions or hypersensitivity to any drug
- On-going regular use of oral prescription drugs, with the exception of oral contraceptives
- Hospitalization for any reason within 8 weeks prior to study dosing
- Participation in any experimental study or ingested any experimental drug within 30 days preceding study
- Donation or loss of 450 mL or more of blood within the 3 months prior to Screening/Baseline
- Subject consumed alcohol 48 hours prior to the baseline measurements of the study
- Subject reports history of human immunodeficiency virus
- Currently using coenzyme Q10 over-the-counter products
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BPM31510 Oral Nanosuspension 4%
Study subjects will self-administer 80 mL (4 vials of 20 mL) of oral BPM31510 (Ubidecarenone, USP; 40 mg/mL) nano-suspension 3 times daily every 4 to 6 hours for a total daily dose 9600 mg/day of BPM31510 for 14 consecutive days.
The last study dose (morning dose only) is administered at the clinic on Day 15.
|
Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax)
Time Frame: Days 1, 2, 5, 15; baseline pre-dosing concentrations
|
Pharmacokinetic (PK) samples collected to establish oral bioavailability.
|
Days 1, 2, 5, 15; baseline pre-dosing concentrations
|
Area under the plasma concentration curve (AUC0-4)
Time Frame: Days 1, 2, 5, 15; baseline pre-dosing concentrations
|
Pharmacokinetic (PK) samples collected to establish oral bioavailability.
|
Days 1, 2, 5, 15; baseline pre-dosing concentrations
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of study subjects with adverse events
Time Frame: Baseline to 25-35 days after the end of dosing
|
A follow-up phone interview with each study subject will occur 25 to 35 days after the end of dosing to measure the number of adverse events that have occurred.
|
Baseline to 25-35 days after the end of dosing
|
C-reactive protein measurement
Time Frame: Days 1, 2, 5, 15
|
Days 1, 2, 5, 15
|
|
Cholesterol measurement
Time Frame: Days 1, 2, 5, 15
|
Days 1, 2, 5, 15
|
|
Low density lipoprotein (LDL) measurement
Time Frame: Days 1, 2, 5, 15
|
Days 1, 2, 5, 15
|
|
High density lipoprotein (HDL) measurement
Time Frame: Days 1, 2, 5, 15
|
Days 1, 2, 5, 15
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Magdy Shenouda, MD, Clinilabs, Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BP 0312-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on BPM31510 Oral Nanosuspension 4%
-
Berg, LLCCompleted
-
Berg, LLCCompletedPancreatic CancerUnited States, United Kingdom
-
Gadjah Mada UniversityCompletedPreterm | Very Low Birth Weight Baby | Trophic FeedingIndonesia
-
University of Alabama at BirminghamEli Lilly and CompanyNot yet recruitingFrontal Fibrosing AlopeciaUnited States
-
ReveraGen BioPharma, Inc.WithdrawnPediatric Ulcerative Colitis
-
Shanghai Zhongshan HospitalWest China Hospital; Tongji Hospital; Anhui Provincial HospitalUnknownHepatocellular Carcinoma (HCC)China
-
University of North Carolina, Chapel HillEli Lilly and CompanyRecruitingLichen Planus, Oral | Oral Lichen Planus | Lichen Planus, MucosalUnited States
-
Texas A&M UniversityCompletedSnoring | Obstructive Sleep Apnea | Mouth BreathingUnited States
-
Medibiofarma S.L.CompletedSafety and PharmacokineticSpain
-
Shanghai Zhongshan HospitalWest China Hospital; Tongji Hospital; Anhui Provincial HospitalUnknownHepatocellular Carcinoma (HCC)China